Impax Laboratories Company Profile (NASDAQ:IPXL)

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:IPXL
  • CUSIP: 45256B10
  • Web:
  • Market Cap: $1.38189 billion
  • Outstanding Shares: 73,701,000
Average Prices:
  • 50 Day Moving Avg: $16.33
  • 200 Day Moving Avg: $13.85
  • 52 Week Range: $7.75 - $31.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.30
  • P/E Growth: 2.90
Sales & Book Value:
  • Annual Revenue: $783.32 million
  • Price / Sales: 1.83
  • Book Value: $7.55 per share
  • Price / Book: 2.57
  • EBIDTA: $148.9 million
  • Net Margins: -71.50%
  • Return on Equity: 7.71%
  • Return on Assets: 3.23%
  • Debt-to-Equity Ratio: 1.41%
  • Current Ratio: 1.74%
  • Quick Ratio: 1.17%
  • Average Volume: 1.75 million shs.
  • Beta: 1.17
  • Short Ratio: 3.94
Frequently Asked Questions for Impax Laboratories (NASDAQ:IPXL)

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) issued its quarterly earnings data on Wednesday, May, 10th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by $0.01. The business had revenue of $184.40 million for the quarter, compared to analyst estimates of $193.17 million. Impax Laboratories had a negative net margin of 71.50% and a positive return on equity of 7.71%. The firm's quarterly revenue was down 18.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share. View Impax Laboratories' Earnings History.

What guidance has Impax Laboratories issued on next quarter's earnings?

Impax Laboratories issued an update on its FY17 earnings guidance on Wednesday, May, 10th. The company provided earnings per share guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.71.

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?

13 equities research analysts have issued twelve-month price objectives for Impax Laboratories' stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Impax Laboratories' stock price to reach $19.69 in the next twelve months. View Analyst Ratings for Impax Laboratories.

What are analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • 1. According to Zacks Investment Research, "Impax’s Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. However, the epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. The company is also taking steps to reduce costs and improve efficiencies, which is estimated to save a total of $130 million by the end of 2019. However, the company’s 2017 earnings guidance is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to hurt revenues. Moreover, the company’s manufacturing facilities had been hampered by quality control issues since 2011 and an inspection had even delayed Rytary’s approval. Impax is also involved in a patent litigation regarding approval of generic version of Rytary. Estimates have been mostly stable ahead of the Q2 results. Impax does not have an impressive record of earnings surprises in the recent quarters." (7/24/2017)
  • 2. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
  • 3. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)
  • 4. BMO Capital Markets analysts commented, "an opportunistic one for IPXL and could drive some upside to our Adrenaclick forecasts." (1/13/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a decrease in short interest in the month of June. As of June 15th, there was short interest totalling 7,670,468 shares, a decrease of 15.0% from the May 31st total of 9,029,063 shares. Based on an average daily volume of 1,564,712 shares, the days-to-cover ratio is presently 4.9 days. Approximately 10.7% of the shares of the stock are short sold.

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:

  • Robert L. Burr, Independent Chairman of the Board
  • Paul M. Bisaro, President, Chief Executive Officer, Director
  • Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
  • Douglas S. Boothe, President - Generics Division
  • Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
  • Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
  • Jeffrey D. Nornhold, Senior Vice President - Technical Operations
  • J. Kevin Buchi, Director
  • Janet S. Vergis, Director
  • Leslie Z. Benet Ph.D., Independent Director

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by many different of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (1.05%), Aperio Group LLC (0.08%), Bank of Montreal Can (0.08%), Fox Run Management L.L.C. (0.05%), Louisiana State Employees Retirement System (0.04%) and Legato Capital Management LLC (0.03%). Company insiders that own Impax Laboratories stock include Leslie Z Benet, Mark A Schlossberg, Michael Markbreiter, Michael Nestor and Peter R Terreri. View Institutional Ownership Trends for Impax Laboratories.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC and Capstone Asset Management Co.. Company insiders that have sold Impax Laboratories stock in the last year include Leslie Z Benet and Michael Nestor. View Insider Buying and Selling for Impax Laboratories.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Aperio Group LLC, Legato Capital Management LLC, Appleton Partners Inc. MA, State of Alaska Department of Revenue and Bank of Montreal Can. View Insider Buying and Selling for Impax Laboratories.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of Impax Laboratories stock can currently be purchased for approximately $19.40.

MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  376 (Vote Underperform)
Total Votes:  607
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.23)
Consensus Price Target: $19.69 (1.51% upside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Piper Jaffray CompaniesUpgradeUnderweight -> Neutral$9.00 -> $16.00LowView Rating Details
7/17/2017Deutsche Bank AGSet Price TargetBuy$20.00 -> $21.00LowView Rating Details
7/16/2017Royal Bank Of CanadaSet Price TargetHold$15.00HighView Rating Details
6/23/2017BMO Capital MarketsReiterated RatingHold$16.00LowView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$20.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00HighView Rating Details
3/27/2017GuggenheimReiterated RatingBuy$20.00LowView Rating Details
3/8/2017Susquehanna Bancshares IncDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of America CorporationDowngradeNeutral -> Underperform$19.00N/AView Rating Details
9/27/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$25.00 -> $26.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoInitiated CoverageNeutral$47.00N/AView Rating Details
4/15/2016BTIG ResearchReiterated RatingBuy$48.00N/AView Rating Details
3/2/2016NomuraReiterated RatingHoldN/AView Rating Details
2/17/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Impax Laboratories (NASDAQ:IPXL)
Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)
Earnings History by Quarter for Impax Laboratories (NASDAQ IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
2017 EPS Consensus Estimate: $0.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.13$0.13$0.13
Q2 20171$0.17$0.17$0.17
Q3 20171$0.22$0.22$0.22
Q4 20171$0.35$0.35$0.35
(Data provided by Zacks Investment Research)


Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 83.84%
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Michael NestorInsiderSell1,130$15.00$16,950.00View SEC Filing  
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Impax Laboratories (NASDAQ:IPXL)
Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
DateHeadline logoImpax Laboratories, Inc. (IPXL) Cut to Strong Sell at Zacks Investment Research - July 24 at 1:04 PM logoZacks: Brokerages Expect Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $196.18 Million - July 23 at 9:18 AM logo$0.14 EPS Expected for Impax Laboratories, Inc. (IPXL) This Quarter - July 21 at 12:32 PM logoBiotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta - July 18 at 4:50 PM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Price Target Raised to $21.00 - July 17 at 7:15 PM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Stock Rating Lowered by Zacks Investment Research - July 17 at 3:28 PM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Given "Hold" Rating at Royal Bank Of Canada - July 16 at 7:32 AM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Lifted to Buy at Zacks Investment Research - July 11 at 4:52 PM logoCantor Fitzgerald Comments on Impax Laboratories, Inc.'s FY2017 Earnings (NASDAQ:IPXL) - July 6 at 9:16 AM logoImpax Announces FDA Approval and Launch of Additional Strengths of Generic Focalin XR® (Dexmethylphenidate Hydrochloride) Extended-Release Capsules CII - July 6 at 6:35 AM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Receives Average Rating of "Hold" from Analysts - July 3 at 10:59 AM logo Brokerages Expect Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $196.18 Million - June 29 at 11:42 AM logoImpax Laboratories, Inc. (IPXL) Short Interest Update - June 29 at 7:14 AM logo Analysts Anticipate Impax Laboratories, Inc. (IPXL) to Announce $0.14 EPS - June 27 at 8:32 AM logoImpax Laboratories' (IPXL) "Hold" Rating Reaffirmed at BMO Capital Markets - June 24 at 9:34 AM logoToday's Research Reports on Stocks to Watch: Agenus and Impax Laboratories - June 21 at 3:40 PM logoImpax Laboratories' (IPXL) "Hold" Rating Reiterated at Royal Bank Of Canada - June 18 at 8:20 PM logoImpax Laboratories, Inc. (IPXL) Now Covered by Cantor Fitzgerald - June 16 at 10:06 AM logoImpax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : June 15, 2017 - June 16 at 6:13 AM logoImpax Laboratories' (IPXL) Neutral Rating Reiterated at Janney Montgomery Scott - June 12 at 10:16 AM logoShort Interest in Impax Laboratories, Inc. (IPXL) Decreases By 13.5% - June 12 at 7:08 AM logoEndo's Pain Is Good For Collegium, Mixed For Impax - June 9 at 3:29 PM logoHow Endo's Opioid Pitfall Could Be A Boon For These Drugmakers - June 9 at 3:29 PM logoImpax Laboratories Breaks Above 200-Day Moving Average - Bullish for IPXL - June 8 at 6:56 PM logoImpax Laboratories Inc (IPXL) Given Consensus Recommendation of "Hold" by Analysts - June 6 at 10:33 AM logoZacks: Brokerages Anticipate Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $196.18 Million - June 3 at 10:04 AM logoImpax Laboratories Inc (IPXL) Insider Sells $16,950.00 in Stock - June 1 at 4:50 PM logo Brokerages Anticipate Impax Laboratories Inc (IPXL) Will Announce Earnings of $0.14 Per Share - June 1 at 7:44 AM logoShort Interest in Impax Laboratories Inc (IPXL) Grows By 20.7% - May 26 at 7:10 AM logoMichael Nestor Sells 857 Shares of Impax Laboratories Inc (IPXL) Stock - May 17 at 4:52 PM logoMichael Nestor Sells 700 Shares of Impax Laboratories Inc (IPXL) Stock - May 15 at 10:57 PM logoImpax Laboratories Inc (IPXL) Sees Significant Growth in Short Interest - May 13 at 7:34 AM logoImpax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 3:35 PM logoImpax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by Brokerages - May 12 at 10:37 AM logoRoyal Bank of Canada Reaffirms "Outperform" Rating for Impax Laboratories Inc (IPXL) - May 11 at 5:58 PM logoImpax Reports First Quarter 2017 Financial Results - May 11 at 4:18 AM logoEdited Transcript of IPXL earnings conference call or presentation 10-May-17 12:30pm GMT - May 10 at 11:16 PM logoImpax Laboratories Inc (IPXL) Announces Quarterly Earnings Results - May 10 at 3:32 PM logoImpax Laboratories (IPXL) Q1 2017 Results - Earnings Call Transcript - May 10 at 1:15 PM logoInvestor Network: Impax Laboratories, Inc. to Host Earnings Call - May 10 at 1:15 PM logoTuring Rejects $100 Million Offer For Daraprim - May 10 at 12:35 PM logoImpax Laboratories Inc (IPXL) Expected to Announce Quarterly Sales of $190.7 Million - May 10 at 12:33 PM logoImpax Laboratories Inc (IPXL) Issues FY17 Earnings Guidance - May 10 at 9:36 AM logoImpax Labs reports 1Q loss - May 10 at 5:19 AM logoImpax Laboratories Inc (IPXL) Raised to "Hold" at Zacks Investment Research - May 8 at 3:34 PM logoZacks: Brokerages Expect Impax Laboratories Inc (IPXL) to Post $0.11 Earnings Per Share - May 8 at 10:32 AM logoImpax Laboratories (IPXL) Getting Somewhat Positive Media Coverage, Study Shows - May 4 at 8:52 PM logoSomewhat Positive News Coverage Likely to Impact Impax Laboratories (IPXL) Share Price - April 30 at 6:05 PM logoImpax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tablets) - April 26 at 7:23 PM logoVetr Crowd Urges Sell For Impax Laboratories - April 25 at 10:40 AM



Impax Laboratories (IPXL) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff